Holen Sie sich die Stockscreener-App
8.51
1.79%
0.15
Handel nachbörslich:
8.51
Schlusskurs vom Vortag:
$8.36
Offen:
$8.36
24-Stunden-Volumen:
69,675
Relative Volume:
0.86
Marktkapitalisierung:
$490.87M
Einnahmen:
$154.57M
Nettoeinkommen (Verlust:
$15.07M
KGV:
31.52
EPS:
0.27
Netto-Cashflow:
$10.92M
1W Leistung:
+5.06%
1M Leistung:
+5.85%
6M Leistung:
+15.94%
1J Leistung:
+6.37%
1-Tages-Spanne:
$8.305
$8.62
1-Wochen-Bereich:
$7.975
$8.62
52-Wochen-Spanne:
$5.54
$8.88
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
8.51 | 482.22M | 154.57M | 15.07M | 10.92M | 0.27 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | The Benchmark Company | Buy |
| 2024-07-03 | Eingeleitet | Stifel | Buy |
| 2018-02-02 | Eingeleitet | Chardan Capital Markets | Buy |
Kamada Ltd Aktie (KMDA) Neueste Nachrichten
Weekly Earnings: Is Kamada Ltd stock a buy or sellWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Sentiment Review: Is Kamada Ltd exposed to political riskCEO Change & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Is Kamada Ltd exposed to political riskWeekly Trading Summary & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Intraday: Can Kamada Ltd navigate macro headwindsPortfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Kamada (TLV:KMDA) shareholder returns have been favorable, earning 74% in 3 years - simplywall.st
Can Kamada Ltd. continue delivering strong returnsJuly 2025 Gainers & Verified Chart Pattern Signals - mfd.ru
Pharma News: Will Kamada Ltd outperform the market in YEAR2025 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn
Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock? - Yahoo Finance
Volume Summary: Is Kamada Ltd a potential multi baggerTrade Entry Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Kamada Ltd. (KMDA) Stock Analysis: Exploring a 62.91% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Kamada Ltd: Biopharma under Pressure as KMDA Stock Tests Investor Patience - AD HOC NEWS
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - openPR.com
Is Kamada Ltd. stock a safe investment in uncertain marketsSector ETF Performance & Fast Growing Trading Plans - Bollywood Helpline
Kamada Ltd. (KMDA) Stock Analysis: Exploring A 58.15% Upside In The Healthcare Space - DirectorsTalk Interviews
Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio | Corporate - EQS News
Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio - NewMediaWire
Kamada Projects Strong 2026 Growth Fueled by Plasma Portfolio and Distribution Expansion - citybuzz -
Kamada shares climb after upbeat 2026 outlook points to double-digit growth - MSN
HC Wainwright Issues Optimistic Forecast for Kamada Earnings - Defense World
Kamada shares drop as company halts Phase 3 study of inhaled AAT therapy - MSN
Q1 Earnings Forecast for Kamada Issued By HC Wainwright - Defense World
Kamada Ltd. (KMDA) Stock Analysis: Unpacking a 63.52% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Q1 Earnings Estimate for Kamada Issued By HC Wainwright - MarketBeat
Can Kamada Ltd. stock attract ESG capital inflowsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - Улправда
Benchmark reiterates Buy rating on Kamada stock, maintains $15 target By Investing.com - Investing.com Nigeria
Benchmark reiterates Buy rating on Kamada stock, maintains $15 target - Investing.com
Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers (NASDAQ:KMDA) - Seeking Alpha
Kamada (KMDA) Projects Strong Revenue and EBITDA Growth by 2026 - GuruFocus
Kamada forecasts double-digit profitable growth in 2026 - MSN
Kamada stock rises after issuing 2026 guidance showing double-digit growth - Investing.com Nigeria
Kamada stock rises after issuing 2026 guidance showing double-digit growth By Investing.com - Investing.com South Africa
Kamada forecasts 13% revenue growth in 2026, issues guidance - Investing.com
Kamada forecasts 13% revenue growth in 2026, issues guidance By Investing.com - Investing.com Nigeria
Kamada Provides 2026 Annual Guidance of $200$205 Million in Revenues and $50$53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance - marketscreener.com
Kamada (NASDAQ:KMDA) Stock Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
Kamada Ltd. (KMDA) Stock Analysis: Unearthing an 84% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Leasing LimitedFundamental Strength Indicators & Free Exceptional ROI Methods - bollywoodhelpline.com
Kamada (NASDAQ:KMDA) Shares Pass Above 50-Day Moving AverageTime to Sell? - MarketBeat
Kamada (NASDAQ:KMDA) Shares Pass Above 50-Day Moving Average – Time to Sell? - Defense World
Kamada (KMDA) price target decreased by 11.86% to 13.26 - MSN
Kamada (KMDA) Stock Analysis Report | Financials & Insights - Benzinga
Kamada Ltd.(NasdaqGS: KMDA) added to NASDAQ Biotechnology Index - marketscreener.com
Is Kamada Ltd. stock affected by interest rate hikesInsider Selling & Long-Term Growth Plans - Улправда
Finanzdaten der Kamada Ltd-Aktie (KMDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):